The British pharma giant said Emma Walmsley's current pay could put off candidates for her eventual successor.

The court directed the firm to pay Ms Gichuki 10 months’ salary as compensation would be adequate in the circumstances ...

The market was pleased with the recent earnings report from GSK plc ( LON:GSK ), despite the profit numbers being ...

One of the most highly anticipated FDA decisions this month is for Alnylam Pharmaceuticals, which is seeking to expand the ...

GSK’s ViiV Healthcare has shared clinical data on three potential long-acting HIV treatments, providing a look at how its ...

Jemperli added £149 million to GSK’s top line compared with £130 million in third-quarter 2024, driven by increased patient uptake in the United States following approval for a broader patient ...

GSK now says earnings in 2014 will be in line with last year, having previously said it expected growth of 4 to 8 per cent. Witty said on the results call that in the last three months the ...

One of the lowest paid CEOs in pharma—and one of the only woman leading a top-tier giant—is set to receive up to $27.2 ...

GSK completes acquisition of Boston-based, clinical-stage biopharma company, IDRx, Inc.

GSK could double its long-serving CEO Emma Walmsley’s pay packet to £21.6 million ($27.2 million) after admitting its boss's current pay didn’t reward her performance and would put off future ...